Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
House dust mite allergen-specific immunoglobulin E (IgE) is a specialized class of antibodies produced by the immune system in response to exposure to house dust mite (HDM) allergens, primarily from the species Dermatophagoides pteronyssinus and Dermatophagoides farinae. In sensitized individuals, these specific IgE antibodies bind to high-affinity Fc epsilon RI receptors on the surface of mast cells and basophils. Upon subsequent exposure to HDM allergens (such as Der p 1, Der p 2, or Der p 23), the allergens cross-link the bound IgE, triggering the degranulation of these effector cells and the release of inflammatory mediators like histamine, leukotrienes, and cytokines. This cascade drives the clinical manifestations of HDM allergy, including allergic rhinitis, allergic asthma, and atopic dermatitis.
Therapeutic strategies targeting HDM-specific IgE include monoclonal antibodies and allergen immunotherapy (AIT). Omalizumab, an anti-IgE monoclonal antibody, binds to circulating free IgE, preventing its interaction with Fc epsilon RI and downregulating receptor expression on effector cells. Conversely, HDM allergen immunotherapies (such as sublingual tablets like Odactra/Acarizax) deliver controlled doses of HDM allergens to desensitize the immune system. This process gradually reduces allergen-specific IgE levels, promotes the production of protective 'blocking' IgG4 antibodies, and induces regulatory T and B cells to restore immune tolerance.
Omalizumab and ligelizumab neutralize circulating free IgE, preventing its binding to high-affinity Fc epsilon RI receptors on mast cells and basophils, thereby inhibiting allergen-induced degranulation. Allergen immunotherapy (e.g., Odactra) delivers controlled doses of house dust mite allergens to bind specific IgE, gradually desensitizing the immune system, promoting the production of protective IgG4 blocking antibodies, and shifting the immune response from Th2 to Th1/Treg.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House dust mite allergen-specific immunoglobulin E (HDM-specific IgE).